Holen Sie sich die Stockscreener-App
8.41
0.34%
-0.07
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
XERS Looks 54.7% Overvalued on GF Value™ as Clinical Update Appr - GuruFocus
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS) - Stock Titan
An estimated 3 to 5 million lack thyroid control. Xeris is developing a weekly injection. - Stock Titan
Xeris Biopharma Holdings Inc. (XERS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com South Africa
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares - Investing.com
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Nigeria
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CLO Beth Hecht Sells 16,666 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma COO Kevin McCulloch Sells 15,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma Holdings Inc. (XERS) Peer Comparison – Compare with Others - Value Research
Xeris Biopharma stock holds at $8.48 after earnings miss - AD HOC NEWS
Xeris Biopharma Holdings Inc. (XERS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xeris Biopharma Holdings, Inc. (0A8E.L) Stock Price, News, Quote & History - Yahoo Finance
Xeris Announces Details for XP-8121 Program Overview Webinar - Yahoo Finance
XERS | Xeris Biopharma Holdings, Inc. FinancialsRevenue Breakdown - quiverquant.com
Xeris Biopharma CEO John Patrick Shannon Jr. Reports Share Withholding for RSU Tax Settlement - Kalkine Media
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Xeris Biopharma posts record $203M revenue in 2... - Pluang
Xeris (XERS) Financial Results: EPS Does Not Reach the Reported Estimate in the Available Record; Price Move - vinanet.vn
Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Sahm
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues - Sahm
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
XERS Q2 2026 Earnings: Steep EPS Miss Weighs on SharesFinancial Summary - vinanet.vn
XERS|Xeris Biopharma Holdings Inc|Price:8.500|Chg%:-0.100 - TradingKey
XERS Q2 2026 Earnings: Significant EPS Miss Weighs on SharesRevenue Per Share - Vinanet
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock - MarketBeat
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares - Stock Titan
HC Wainwright Comments on Xeris Biopharma FY2026 Earnings - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS - webull.com
HC Wainwright Expects Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) options chain – Yahoo Finance - Yahoo Finance Singapore
Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses - Sahm
Xeris Biopharma (NASDAQ:XERS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Stock News Today - TradingKey
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Lucrative 53% Upside Potential for Investors - DirectorsTalk Interviews
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call High - GuruFocus
XERS Looks 53.1% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary - TradingView
Xeris raises outlook despite posting $31.1 million loss - Crain's Chicago Business
Xeris Biopharma (NASDAQ:XERS) Shares Gap Down Following Weak Earnings - MarketBeat
Is Xeris Biopharma Holdings Inc (XERS) Still a Smart Investment? - GuruFocus
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss - Investing.com
Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M$390M, vs. FactSet Est of $385.9M - marketscreener.com
Q2 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma: Q2 Earnings Snapshot - marketscreener.com
XERS: Q2 2026 revenue grew 34% year-over-year, driven by Recorlev, with improved margins and strong outlook - TradingView
Xeris Biopharma Reports Second Quarter 2026 Financial Results - Business Wire
0.20%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):